Lataa...
Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
Knowledge regarding the mechanisms of the IL17–IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroid...
Tallennettuna:
| Julkaisussa: | Front Med (Lausanne) |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5241317/ https://ncbi.nlm.nih.gov/pubmed/28149838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2017.00001 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|